The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study

被引:41
|
作者
Phakdeekitcharoen, Bunyong [1 ]
Boonyawat, Kochawan [1 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Nephrol,Dept Med, Bangkok 10400, Thailand
来源
BMC NEPHROLOGY | 2012年 / 13卷
关键词
Chronic kidney disease (CKD); Furosemide; Albumin; Edema; CONGESTIVE-HEART-FAILURE; HUMAN-SERUM-ALBUMIN; NEPHROTIC SYNDROME; RESISTANCE; FRUSEMIDE; PHARMACOKINETICS; MECHANISMS; EDEMA;
D O I
10.1186/1471-2369-13-92
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic kidney disease (CKD) with edema is a common clinical problem resulting from defects in water and solute excretion. Furosemide is the drug of choice for treatment. In theory, good perfusion and albumin are required for the furosemide to be secreted at the tubular lumen. Thus, in the situation of low glomerular filtration rate (GFR) and hypoalbuminemia, the efficacy of furosemide alone might be limited. There has been no study to validate the effectiveness of the combination of furosemide and albumin in this condition. Methods: We conducted a randomized controlled crossover study to compare the efficacy of diuretics between furosemide alone and the combination of furosemide plus albumin in stable hypoalbuminemic CKD patients by measuring urine output and sodium. The baseline urine output/sodium at 6 and 24 hours were recorded. The increment of urine output/sodium after treatment at 6 and 24 hours were calculated by using post-treatment minus baseline urine output/sodium at the corresponding period. Results: Twenty-four CKD patients (GFR = 31.0 +/- 13.8 mL/min) with hypoalbuminemia (2.98 +/- 0.30 g/dL) were enrolled. At 6 hours, there were significant differences in the increment of urine volume (0.47 +/- 0.40 vs 0.67 +/- 0.31 L, P < 0.02) and urine sodium (37.5 +/- 29.3 vs 55.0 +/- 26.7 mEq, P < 0.01) between treatment with furosemide alone and with furosemide plus albumin. However, at 24 hours, there were no significant differences in the increment of urine volume (0.49 +/- 0.47 vs 0.59 +/- 0.50 L, P = 0.46) and urine sodium (65.3 +/- 47.5 vs 76.1 +/- 50.1 mEq, P = 0.32) between the two groups. Conclusion: The combination of furosemide and albumin has a superior short-term efficacy over furosemide alone in enhancing water and sodium diuresis in hypoalbuminemic CKD patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease-the ASSUAGE-CKD trial
    Doukky, Rami
    Rangel, Maria Octavia
    Dick, Rizcallah
    Wassouf, Marwan
    Alqaid, Ammar
    Margeta, Bosko
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2013, 29 (05) : 1029 - 1037
  • [42] Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up
    Makhlough, Atieh
    Shekarchian, Soroosh
    Moghadasali, Reza
    Einollahi, Behzad
    Dastgheib, Mona
    Janbabaee, Ghasem
    Hosseini, Seyedeh Esmat
    Falah, Nasrin
    Abbasi, Fateme
    Baharvand, Hossein
    Aghdami, Nasser
    CYTOTHERAPY, 2018, 20 (05) : 660 - 669
  • [43] Effects of individualized exercise program on physical function, psychological dimensions, and health-related quality of life in patients with chronic kidney disease: A randomized controlled trial in China
    Tang, Qing
    Yang, Bin
    Fan, Fengyan
    Li, Ping
    Yang, Lei
    Guo, Yujie
    INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2017, 23 (02)
  • [44] TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease-a prospective follow-up study
    Lorenzen, Johan M.
    David, Sascha
    Richter, Alena
    de Groot, Kirsten
    Kielstein, Jan T.
    Haller, Hermann
    Thum, Thomas
    Fliser, Danilo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (04) : 1421 - 1424
  • [45] Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study
    Tominaga, Naoto
    Kida, Keisuke
    Inomata, Takayuki
    Sato, Naoki
    Izumi, Tohru
    Akashi, Yoshihiro J.
    Shibagaki, Yugo
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (05) : 417 - 426
  • [46] Minimisation of dialysis risk in hospital patients with chronic kidney disease (MinDial): study protocol for a multicentre, stepped-wedge, cluster-randomised controlled trial
    Stelzer, D.
    Binder, H.
    Glattacker, M.
    Graf, E.
    Hahn, M.
    Hollenbeck, M.
    Kaier, K.
    Kowall, B.
    Kuklik, N.
    Metzner, G.
    Mueller, N.
    Seiler, L.
    Stolpe, S.
    Blume, C.
    TRIALS, 2024, 25 (01)
  • [47] Association between alkaline phosphatase/albumin ratio and the prognosis in patients with chronic kidney disease stages 1-4: results from a C-STRIDE prospective cohort study
    Xue, Xue
    Li, Jia-Xuan
    Wang, Jin-Wei
    Lin, La-Mei
    Cheng, Hong
    Deng, Dan-Fang
    Xu, Wen-Cheng
    Zhao, Yu
    Zou, Xin-Rong
    Yuan, Jun
    Zhang, Lu-Xia
    Zhao, Ming-Hui
    Wang, Xiao-Qin
    FRONTIERS IN MEDICINE, 2023, 10
  • [48] Update to the study protocol: minimisation of dialysis risk in hospital patients with chronic kidney disease (MinDial): a multicentre, stepped-wedge, cluster-randomised controlled trial
    Stelzer, D.
    Binder, H.
    Glattacker, M.
    Graf, E.
    Hahn, M.
    Hollenbeck, M.
    Kaier, K.
    Kowall, B.
    Kuklik, N.
    Metzner, G.
    Mueller, N.
    Seiler, L.
    Stolpe, S.
    Blume, C.
    TRIALS, 2024, 25 (01)
  • [49] Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study
    Tsuruya, Kazuhiko
    Hayashi, Terumasa
    Yamamoto, Hiroyasu
    Hase, Hiroki
    Nishi, Shinichi
    Yamagata, Kunihiro
    Nangaku, Masaomi
    Wada, Takashi
    Uemura, Yukari
    Ohashi, Yasuo
    Hirakata, Hideki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 456 - 466
  • [50] Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study
    Ash, Stephen R.
    Batlle, Daniel
    Kendrick, Jessica
    Oluwatosin, Yemisi
    Pottorf, William
    Brahmbhatt, Yasmin
    Guerrieri, Emily
    Fried, Linda
    NEPHRON, 2022, 146 (06) : 599 - 609